| 000 | 01773 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517052516.0 | ||
| 264 | 0 | _c20160922 | |
| 008 | 201609s 0 0 eng d | ||
| 022 | _a1873-7064 | ||
| 024 | 7 |
_a10.1016/j.neuropharm.2015.09.006 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPark, Keun Hong | |
| 245 | 0 | 0 |
_aL-DOPA modulates cell viability through the ERK-c-Jun system in PC12 and dopaminergic neuronal cells. _h[electronic resource] |
| 260 |
_bNeuropharmacology _cFeb 2016 |
||
| 300 |
_a87-97 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdrenergic Agents _xtoxicity |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCaspase 3 _xmetabolism |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 |
_aDopamine Agents _xpharmacology |
| 650 | 0 | 4 |
_aDopaminergic Neurons _xdrug effects |
| 650 | 0 | 4 | _aEmbryo, Mammalian |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aGene Expression Regulation _xdrug effects |
| 650 | 0 | 4 |
_aLevodopa _xpharmacology |
| 650 | 0 | 4 |
_aMAP Kinase Signaling System _xdrug effects |
| 650 | 0 | 4 |
_aMesencephalon _xcytology |
| 650 | 0 | 4 |
_aOxidopamine _xtoxicity |
| 650 | 0 | 4 | _aPC12 Cells |
| 650 | 0 | 4 |
_aParkinson Disease _xetiology |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-jun _xmetabolism |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aShin, Keon Sung | |
| 700 | 1 | _aZhao, Ting Ting | |
| 700 | 1 | _aPark, Hyun Jin | |
| 700 | 1 | _aLee, Kyung Eun | |
| 700 | 1 | _aLee, Myung Koo | |
| 773 | 0 |
_tNeuropharmacology _gvol. 101 _gp. 87-97 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.neuropharm.2015.09.006 _zAvailable from publisher's website |
| 999 |
_c25254657 _d25254657 |
||